Novartis AG ADR (NVS) - Stock Price & Dividends

Exchange: USA Stocks • Country: Switzerland • Currency: USD • Type: Common Stock • ISIN: US66987V1098

Novartis AG is a global healthcare company based in Switzerland. They are dedicated to researching, developing, manufacturing, and promoting healthcare products internationally. Their focus areas include cardiovascular, renal and metabolic, immunology, neuroscience, oncology, ophthalmology, and hematology. The company prides itself on providing prescription medicines for both patients and healthcare professionals.

Novartis AG has formed a strategic partnership with Alnylam Pharmaceuticals to work on inclisiran, a therapy designed to lower LDL cholesterol levels. This collaboration aims to develop, manufacture, and commercialize this innovative treatment. Novartis AG was established in 1996 and has its headquarters in Basel, Switzerland. To learn more about the company, you can visit their official website at

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Novartis AG ADR (NVS) - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Novartis AG ADR (NVS) - Stock Price & Dividends

NVS Stock Overview

Market Cap in USD 197,719m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 1991-11-18

NVS Stock Ratings

Growth 5y 6.05
Fundamental 6.38
Dividend 8.07
Rel. Performance vs Sector 0.08
Analysts 3.50/5
Fair Price Momentum 85.35 USD
Fair Price DCF 157.70 USD

NVS Dividends

Yield 12m 4.00%
Yield on Cost 5y 6.41%
Dividends CAGR 5y 6.21%
Payout Consistency 96.2%

NVS Growth Ratios

Growth 12m 5.73%
Growth Correlation 12m 41%
Growth Correlation 3m -64%
CAGR 5y 9.89%
Sharpe Ratio 12m 0.03
Alpha vs SP500 12m -9.19
Beta vs SP500 5y weekly 0.53
ValueRay RSI 18.43
Volatility GJR Garch 1y 19.15%
Price / SMA 50 -2.97%
Price / SMA 200 -0.54%
Current Volume 1501k
Average Volume 20d 1620.8k

External Links for NVS Stock

Wall Street JournalBenzingaYahoo Finance
X (Twitter)Stocktwits
Fund Manager Positions
What is the price of NVS stocks?
As of April 16, 2024, the stock is trading at USD 94.41 with a total of 1,501,028 shares traded.
Over the past week, the price has changed by -1.12%, over one month by -2.94%, over three months by -8.98% and over the past year by +5.83%.
What is the forecast for NVS stock price target?
According to ValueRays Forecast Model, NVS Novartis AG ADR will be worth about 93.6 in April 2025. The stock is currently trading at 94.41. This means that the stock has a potential downside of -0.88%.
Issuer Forecast Upside
Wallstreet Target Price 113 19.7%
Analysts Target Price 112.8 19.4%
ValueRay Target Price 93.6 -0.88%

Understanding Novartis AG ADR (NVS): A Comprehensive Overview

History of Novartis AG ADR

Novartis AG, a global healthcare company based in Switzerland, has a rich history that stretches back more than 250 years. It was formed in 1996 through the merger of two Swiss companies, Ciba-Geigy and Sandoz. These companies were themselves the result of several mergers and acquisitions over the years, making Novartis one of the oldest and most diversified healthcare companies in the world.

Core Business

Novartis focuses on three main sectors within the healthcare industry: pharmaceuticals, eye care, and generics through its Sandoz division. In the pharmaceuticals sector, Novartis is known for producing a wide range of medicines for various diseases, including cancer, heart disease, and more. Its eye care business, primarily under the Alcon brand until it was spun off in 2019, delivered innovative products to improve people’s sight. Sandoz, the generics and biosimilars division, aims to make high-quality medicines more accessible and affordable.

Side Businesses and Innovations

Beyond its core operations, Novartis has continually ventured into new business areas and innovations. Digital health initiatives, personalized medicine, and gene therapy are just a few fields where Novartis has made significant investments. The company is also known for its strong commitment to research and development (R&D), investing billions annually to discover new treatments and medical solutions.

Current Market Status

As of the latest financial results, Novartis AG ADR (NYSE:NVS) remains a giant in the healthcare sector, with a strong presence in over 100 countries. Despite facing challenges such as patent expirations and regulatory pressures, the company has sustained its growth through strategic acquisitions, divestitures, and a focus on high-growth areas in healthcare. The performance of Novartis in the stock market reflects its resilience and adaptability, making it a noteworthy entity in the global pharmaceutical and healthcare industry.